Previous 10 | Next 10 |
Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...
GSK Facing Headwinds in Established Products but Balanced by Growth Opportunities in Oncology GlaxoSmithKline ( GSK ) faces several headwinds in its business, with Advair facing generic pressure and its new two-drug HIV regimen struggling to gain traction. On the latter point, the company mu...
Agenus (NASDAQ: AGEN ) resumed with Buy rating and $6 (36% upside) price target at B. Riley FBR. Shares up 1% premarket. More news on: Agenus Inc., Cabaletta Bio, Inc., Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (...
Continuing with the series of articles on gene therapy, this article will discuss the various delivery methods for gene therapies with a focus on viral vectors. What is transgene? A transgene is a new therapeutic DNA segment that is to be inserted into the host cell. In addition to the g...
Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for patients with sickle cell disease New data from ongoing Phase 3...
Allogene Therapeutics (NASDAQ: ALLO ) initiated with Buy rating and $36 (24% upside) price target at Canaccord Genuity. More news on: Allogene Therapeutics, Inc., BioNTech SE, TCR2 Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The following slide deck was published by bluebird bio, Inc. in conjunction with this Read more ...
bluebird bio (NASDAQ: BLUE ): Q3 GAAP EPS of -$3.73 misses by $0.19 . Revenue of $8.91M (-22.7% Y/Y) misses by $3.56M . Press Release More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news,
- Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined commercial manufacturing process - - Ended quarter with $1.41 billi...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...